Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

Company Overview - Sutro Biopharma, Inc. is focused on the discovery and development of precisely designed cancer therapeutics, particularly antibody drug conjugates (ADCs) [7] - The company is advancing a robust early-stage pipeline of novel exatecan-based and dual-payload ADCs, supported by high-value collaborations and industry partnerships [7] Leadership Appointment - Greg Chow has been appointed as Chief Financial Officer (CFO) effective June 2, 2025, bringing over 25 years of executive leadership experience in corporate finance, capital markets, and drug development operations [1][2] - Chow's previous roles include Chief Financial and Business Officer at NodThera, CFO at Freenome Holdings, and CFO at Frontier Medicines, where he successfully executed significant financing rounds [2][3] Financial Strategy and Goals - The leadership of Greg Chow is expected to enhance financial discipline, operational efficiency, and capital strategy, positioning the company to achieve key clinical milestones [2] - Chow expressed enthusiasm about joining Sutro, highlighting the company's unique position in ADC innovation and its powerful cell-free technology platform for drug discovery [2] Inducement Grants - Sutro has granted Greg Chow a restricted stock unit award for 100,000 shares and a non-qualified option to purchase 275,000 shares under the 2021 Equity Inducement Plan [4][5] - The option will have an exercise price equal to the closing price of Sutro's common stock on the appointment date, with vesting schedules for both the restricted stock and option awards [6]